Brind.

Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.

2 reports, 2 independent Updated Sep 5
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
13
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.

Who's involved

What this event is mainly about
Hoffmann-La RocheSanofiEli Lilly and CompanyRegeneron PharmaceuticalsBiogenGilead

How it developed

Newest first. Tap a step to see who reported it.
  1. Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.Sub-event
  2. Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.Sub-event
  3. Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.Sub-event
  4. Sooin was appointed Chief Business and Strategy Officer at Galapagos, which also announced a partnership with Gilead.Sub-event
  5. Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.Sub-event
  6. TMO expanded a strategic partnership with Sanofi on August 28, 2025.Sub-event
  7. Sales of products including Vivitrol, Aristada, and Lybalvi increased due to strong market demand and new prescriptions.Sub-event
  8. A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.Sub-event
Show 5 earlier steps
  1. Biogen and Eisai are collaborating on the development of Leqembi, targeting early approval and market entry in key European markets like Austria and Germany.Sub-event
  2. Ralph Lauren, Biogen, and Zebra Technologies are currently under scrutiny as mid-cap stocks.Sub-event
  3. Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.Sub-event
  4. Thermo Fisher Scientific acquired Sanofi's factory on September 3, 2025.Sub-event
  5. Leading pharma companies solidify competitive alliances and market presence in immunology, oncology, and ophthalmology.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyRegeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we
  • GlobeNewswireBiogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome – Dur